Výsledky vyhľadávania - "Rhee, Ina"

Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy Autor Hodi, F Stephen, Ballinger, Marcus, Lyons, Benjamin, Soria, Jean-Charles, Nishino, Mizuki, Tabernero, Josep, Powles, Thomas, Smith, David, Hoos, Axel, McKenna, Chris, Beyer, Ulrich, Rhee, Ina, Fine, Gregg, Winslow, Nathan, Chen, Daniel S, Wolchok, Jedd D

“…Purpose Treating solid tumors with cancer immunotherapy (CIT) can result in unconventional responses and overall survival (OS) benefits that are not adequately…”
Zistit podrobnosti o prístupe

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy Autor Rizvi, Naiyer, Ademuyiwa, Foluso O, Cao, Z Alexander, Chen, Helen X, Ferris, Robert L, Goldberg, Sarah B, Hellmann, Matthew D, Mehra, Ranee, Rhee, Ina, Park, Jong Chul, Kluger, Harriet, Tawbi, Hussein, Sullivan, Ryan J

“…Although immunotherapy can offer profound clinical benefit for patients with a variety of difficult-to-treat cancers, many tumors either do not respond to…”
Získať plný text

DNMT1 and DNMT3b cooperate to silence genes in human cancer cells Autor Rhee, Ina, Bachman, Kurtis E., Park, Ben Ho, Jair, Kam-Wing, Yen, Ray-Whay Chiu, Schuebel, Kornel E., Cui, Hengmi, Feinberg, Andrew P., Lengauer, Christoph, Kinzler, Kenneth W., Baylin, Stephen B., Vogelstein, Bert

“…Inactivation of tumour suppressor genes is central to the development of all common forms of human cancer. This inactivation often results from epigenetic…”
Získať plný text

De novo CpG island methylation in human cancer cells Autor Jair, Kam-Wing, Bachman, Kurtis E, Suzuki, Hiromu, Ting, Angela H, Rhee, Ina, Yen, Ray-Whay Chiu, Baylin, Stephen B, Schuebel, Kornel E

“…A major obstacle toward understanding how patterns of abnormal mammalian cytosine DNA methylation are established is the difficulty in quantitating the de novo…”
Zistit podrobnosti o prístupe

Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene Autor Bachman, Kurtis E, Park, Ben Ho, Rhee, Ina, Rajagopalan, Harith, Herman, James G, Baylin, Stephen B, Kinzler, Kenneth W, Vogelstein, Bert

“…We attempted to answer two central questions about epigenetic silencing of the tumor suppressor gene p16(INK4a) in this study: (1) whether the maintenance of…”
Zistit podrobnosti o prístupe

CpG methylation is maintained in human cancer cells lacking DNMT1 Autor Rhee, Ina, Jair, Kam-Wing, Yen, Ray-Whay Chiu, Lengauer, Christoph, Herman, James G., Kinzler, Kenneth W., Vogelstein, Bert, Baylin, Stephen B., Schuebel, Kornel E.

“…Hypermethylation is associated with the silencing of tumour susceptibility genes in several forms of cancer 1 , 2 ; however, the mechanisms responsible for…”
Získať plný text

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer Autor Rojas, Luis A., Sethna, Zachary, Soares, Kevin C., Olcese, Cristina, Pang, Nan, Patterson, Erin, Lihm, Jayon, Ceglia, Nicholas, Guasp, Pablo, Chu, Alexander, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Ruan, Jennifer, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Payne, George, Derhovanessian, Evelyna, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Dobrin, Anton, Sadelain, Michel, Łuksza, Marta, Cohen, Noah, Tang, Laura, Basturk, Olca, Gönen, Mithat, Katz, Seth, Do, Richard Kinh, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Mellman, Ira, Merghoub, Taha, Wolchok, Jedd D., Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Balachandran, Vinod P.

“…Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2 , 3…”
Získať plný text

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors Autor Jung, Kyung Hae, LoRusso, Patricia, Burris, Howard, Gordon, Michael, Bang, Yung-Jue, Hellmann, Matthew D, Cervantes, Andrés, Ochoa de Olza, Maria, Marabelle, Aurelien, Hodi, F Stephen, Ahn, Myung-Ju, Emens, Leisha A, Barlesi, Fabrice, Hamid, Omid, Calvo, Emiliano, McDermott, David, Soliman, Hatem, Rhee, Ina, Lin, Ray, Pourmohamad, Tony, Suchomel, Julia, Tsuhako, Amy, Morrissey, Kari, Mahrus, Sami, Morley, Roland, Pirzkall, Andrea, Davis, S Lindsey

“…IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment,…”
Zistit podrobnosti o prístupe

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer Autor Sethna, Zachary, Guasp, Pablo, Reiche, Charlotte, Milighetti, Martina, Ceglia, Nicholas, Patterson, Erin, Lihm, Jayon, Payne, George, Lyudovyk, Olga, Rojas, Luis A., Pang, Nan, Ohmoto, Akihiro, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Bruno, Emmanuel M., Zhang, Siqi Linsey, Cheng, Charlotte, Elhanati, Yuval, Derhovanessian, Evelyna, Manning, Luisa, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Merghoub, Taha, Wolchok, Jedd D., Basturk, Olca, Gönen, Mithat, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Soares, Kevin C., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Mellman, Ira, Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Balachandran, Vinod P.

“…A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA–lipoplex…”
Získať plný text

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Autor Kim, Tae Won, Burris, Howard A, de Miguel Luken, Maria J, Pishvaian, Michael J, Bang, Yung-Jue, Gordon, Michael, Awada, Ahmad, Camidge, D Ross, Hodi, F Stephen, McArthur, Grant A, Miller, Wilson H, Cervantes, Andres, Chow, Laura Q, Lesokhin, Alexander M, Rutten, Annemie, Sznol, Mario, Rishipathak, Deepali, Chen, Shang-Chiung, Stefanich, Eric, Pourmohamad, Tony, Anderson, Maria, Kim, Jeong, Huseni, Mahrukh, Rhee, Ina, Siu, Lillian L

“…OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory…”
Zistit podrobnosti o prístupe

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial Autor Lopez, Juanita, Powles, Thomas, Braiteh, Fadi, Siu, Lillian L, LoRusso, Patricia, Friedman, Claire F, Balmanoukian, Ani S, Gordon, Michael, Yachnin, Jeffrey, Rottey, Sylvie, Karydis, Ioannis, Fisher, George A, Schmidt, Marcus, Schuler, Martin, Sullivan, Ryan J, Burris, Howard A, Galvao, Vladimir, Henick, Brian S, Dirix, Luc, Jaeger, Dirk, Ott, Patrick A, Wong, Kit Man, Jerusalem, Guy, Schiza, Aglaia, Fong, Lawrence, Steeghs, Neeltje, Leidner, Rom S, Rittmeyer, Achim, Laurie, Scott A, Gort, Eelke, Aljumaily, Raid, Melero, Ignacio, Sabado, Rachel L, Rhee, Ina, Mancuso, Michael R, Muller, Lars, Fine, Gregg D, Yadav, Mahesh, Kim, Leesun, Leveque, Vincent J P, Robert, Alberto, Darwish, Martine, Qi, Ting, Zhu, Jiawen, Zhang, Jingbin, Twomey, Patrick, Rao, Gautham K, Low, Donald W, Petry, Chris, Lo, Amy A, Schartner, Jill M, Delamarre, Lélia, Mellman, Ira, Löwer, Martin, Müller, Felicitas, Derhovanessian, Evelyna, Cortini, Andrea, Manning, Luisa, Maurus, Daniel, Brachtendorf, Sebastian, Lörks, Verena, Omokoko, Tana, Godehardt, Eva, Becker, Dirk, Hawner, Christine, Wallrapp, Christine, Albrecht, Christian, Kröner, Christoph, Tadmor, Arbel D, Diekmann, Jan, Vormehr, Mathias, Jork, Anette, Paruzynski, Anna, Lang, Maren, Blake, Jonathon, Hennig, Oliver, Kuhn, Andreas N, Sahin, Ugur, Türeci, Özlem, Camidge, D Ross

“…Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a…”
Zistit podrobnosti o prístupe

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer Autor von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin

“…Lessons Learned The lack of efficacy associated with anti‐EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non‐small cell…”
Získať plný text

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer Autor García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert

“…Lessons Learned These negative phase II results for parsatuzumab highlight the challenges of developing an agent intended to enhance the efficacy of vascular…”
Získať plný text

Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population Autor Fredrickson, Jill, Serkova, Natalie J., Wyatt, Shelby K., Carano, Richard A.D., Pirzkall, Andrea, Rhee, Ina, Rosen, Lee S., Bessudo, Alberto, Weekes, Colin, de Crespigny, Alex

“…Purpose To assess the feasibility of acquiring vessel size imaging (VSI) metrics using ferumoxytol injections and stock pulse sequences in a multicenter Phase…”
Získať plný text

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer Autor García‐Carbonero, Rocío, van Cutsem, Eric, Rivera, Fernando, Jassem, Jacek, Gore, Ira, Tebbutt, Niall, Braiteh, Fadi, Argiles, Guillem, Wainberg, Zev A., Funke, Roel, Anderson, Maria, McCall, Bruce, Stroh, Mark, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Hurwitz, Herbert

Získať plný text

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors Autor Weekes, Colin D., Rosen, Lee S., Capasso, Anna, Wong, Kit Man, Ye, Weilan, Anderson, Maria, McCall, Bruce, Fredrickson, Jill, Wakshull, Eric, Eppler, Steve, Shon-Nguyen, Quyen, Desai, Rupal, Huseni, Mahrukh, Hegde, Priti S., Pourmohamad, Tony, Rhee, Ina, Bessudo, Alberto

“…Purpose MINT1526A is a monoclonal antibody that blocks the interaction of integrin alpha 5 beta 1 (α5β1) with its extracellular matrix ligands. This phase I…”
Získať plný text

Interaction of Tyrosine-Based Sorting Signals with Clathrin-Associated Proteins Autor Ohno, Hiroshi, Stewart, Jay, Fournier, Marie-Christine, Bosshart, Herbert, Rhee, Ina, Miyatake, Shoichiro, Saito, Takashi, Gallusser, Andreas, Kirchhausen, Tomas, Bonifacino, Juan S.

“…Tyrosine-based signals within the cytoplasmic domain of integral membrane proteins mediate clathrin-dependent protein sorting in the endocytic and secretory…”
Získať plný text

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models Autor Huseni, Mahrukh, Totpal, Klara, Du, Changchun, Dalpozzo, Katie, Zhu, Jing, Rishipathak, Deepali, McNamara, Erin, Jonshtone, Bernadette, Hegde, Priti S, Rhee, Ina, Damico-Beyer, Lisa, Kim, Jeong

Získať plný text

Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models Autor Huseni, Mahrukh, Totpal, Klara, Du, Changchun, Dalpozzo, Katie, Zhu, Jing, Rishipathak, Deepali, McNamara, Erin, Jonshtone, Bernadette, Hegde, Priti S, Rhee, Ina, Damico-Beyer, Lisa, Kim, Jeong

“…BackgroundOX40, a TNFRSF member, is a co-stimulatory molecule expressed on antigen experienced effector T (Teff) and regulatory T (Treg) cells, including…”
Získať plný text

Mutational Analysis of the Fusion Peptide of the Human Immunodeficiency Virus Type 1: Identification of Critical Glycine Residues Autor DELAHUNTY, MARTHA D., RHEE, INA, FREED, ERIC O., BONIFACINO, JUAN S.

“…The ability of human immunodeficiency virus type 1 (HIV-1) to fuse its membrane with the membrane of the target cell is a function of a ∼23-amino-acid…”
Získať plný text